Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China
SGLT-2I & GLP-1RA dual therapy is associated with improved prognosis for lung cancer patients with concurrent T2D. DPP-4I transits from a tumor activator to suppressor when combined with other anti-diabetic drugs. Future studies are needed to examine the underlying biological mechanisms.
Authors
- Zhewen Ren (ORCID: https://orcid.org/0009-0008-0065-4529)
- Z. Jeffrey Chen
- Chao Lei (ORCID: https://orcid.org/0000-0001-5418-8182)
- Zongtao Zhang
- Zhifei Wang (ORCID: https://orcid.org/0000-0003-2437-3189)
- Ziyi Sun
- Yupeng Di (ORCID: https://orcid.org/0000-0001-7075-3559)
Institutions
- Hengshui University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Maastricht University (NL)
- Air Force General Hospital PLA (CN)
- Guang’anmen Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.3389/fonc.2025.1498927
- Citations
- 3
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- China Academy of Chinese Medical Sciences